Wisconsin-based fusion technology company SHINE Technologies has signed a long-term supply agreement with Nucleus RadioPharma for the supply of lutetium-177, a radioisotope used in cancer treatment therapies, including those in development for the treatment of neuroendocrine tumors, prostate cancer, and other solid tumors.